Answers are grounded in this paper and cite their sources.
Retrospective study assesses survival rates and treatment effectiveness in prosthetic valve thrombosis patients, highlighting key predictors.
Background and Objectives: Prosthetic valve thrombosis (PVT) represents a rare but critical complication after heart valve replacement surgery. This study aimed to evaluate patient characteristics, treatment modalities (medical vs. surgical), and clinical outcomes in patients with PVT over a 15-year period, with a particular focus on the impact of New York Heart Association (NYHA) functional class on mortality. Materials and Methods: We retrospectively analyzed 76 patients with confirmed PVT (54 mitral, 20 aortic, and 2 tricuspid; 97.4% mechanical) treated at a single tertiary center between 2005 and2020. The treatment comprised intravenous unfractionated heparin (UFH) alone (n = 29), low-dose tissue plasminogen activator (t-PA) (n = 27), or surgical re-operation (n = 20). Primary endpoints were treatment success, in-hospital mortality, and complications. Results: Overall, the treatment success was 60.5% (46/76) with a 25.0% (19/76) in-hospital mortality. UFH therapy achieved a 67.6% success with a 24.3% mortality. Low-dose t-PA demonstrated a 59.3% success with a significantly lower mortality (7.4%, p = 0.004). The surgery showed a 50% success with a 50% mortality. Patients in the NYHA class III-IV had markedly higher mortality (68.2% vs. 11.1%, p < 0.001) and lower treatment success (27.3% vs. 81.5%, p < 0.001) compared to the NYHA class I-II. A multivariate analysis revealed NYHA III–IV as the strongest predictor of mortality (OR 12.639, 95% CI: 1.905–83.849, p = 0.009). Conclusions: The low-dose t-PA (25 mg total dose) therapy showed the lowest mortality among treatment modalities. The NYHA functional class emerged as the most significant predictor of outcomes, with the class III-IV patients having >12-fold increased mortality risk. These findings support early intervention and suggest that t-PA is a viable first-line option in selected patients.
No takes yet. Share an insight, caveat, or question.
Uzunselvi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: